PhotoCure ASA (OSL:PHO) FFO


OSL:PHO PhotoCure ASA OSL:PHO
78 GF Score
Price kr60.80
GF Value kr74.44
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is PhotoCure ASA FFO?

FFO (Funds from operations) only applies to REITs.

OSL:PHO
78GF Score
PhotoCure ASA OSL:PHO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is PhotoCure ASA (OSL:PHO) Overvalued in 2026?

Based on GuruFocus' analysis, PhotoCure ASA stock appears to be undervalued. The current stock price of kr60.80 is trading 18.3% below its estimated GF Value™ of kr74.44. GuruFocus considers PhotoCure ASA to be Modestly Undervalued.

Key valuation signals for OSL:PHO:

  • FFO:
  • GF Value™: kr74.44 vs. price of kr60.80 (18.3% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the OSL:PHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PhotoCure ASA Business Description

Address Hoffsveien 4, Oslo, NOR, 0275
PhotoCure ASA is a Norway-based business group associated with the research, development, production, distribution, marketing, and sales of pharmaceutical products and specialty pharmaceutical companies. The technology platform of the company is focused on the field of photodynamic diagnosis and treatment of cancer. The company has two operating segments of the group the Commercial franchise and the Development portfolio. It generates prime revenue from the Commercial franchise segment, which includes Hexvix and Cysview products. Its geographical segments are Nordic countries, Germany, France, Austria, the United Kingdom, BeNeLux, Italy, Other European countries, Canada, and the United States.
78GF Score

Get the complete analysis for OSL:PHO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr60.80
Price
kr74.44
GF Value